Cryo-Cell International (CCEL) Stock Price, News & Analysis

Cryo-Cell International, Inc. (CCEL) is a Delaware corporation focused on cellular processing, cryogenic storage, and related cellular therapies. According to company disclosures and regulatory filings, Cryo-Cell is known as the world’s first private cord blood bank to separate and store stem cells, a milestone it reached in 1992. The company’s shares trade on the NYSE American under the symbol CCEL.

Founded in 1989, Cryo-Cell has built its business around the collection, processing, and long-term storage of umbilical cord blood and cord tissue stem cells. More than 500,000 parents from 87 countries have entrusted Cryo-Cell with their baby’s cord blood and cord tissue stem cells, reflecting the company’s long operating history in private cord blood banking. The company reports that it generates revenue primarily from processing and storage fee revenue, with additional contributions from public banking revenue and product revenue.

Core business and segments

Based on company descriptions and segment disclosures, Cryo-Cell is organized into several reportable activities related to stem cell banking and processing. Its cellular processing and cryogenic storage operations focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use. A separate manufacturing activity relates to PrepaCyte-CB, which the company describes as an advanced cord blood processing technology used to process umbilical cord blood stem cells. Cryo-Cell also operates a public cord blood banking program that consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use.

Across recent financial disclosures, Cryo-Cell identifies processing and storage fee revenue as its largest revenue contributor, with smaller amounts from public banking revenue and product revenue. This structure reflects the company’s emphasis on long-term storage contracts with families, complemented by public banking activities and technology-related products.

Private and public cord blood banking

Cryo-Cell positions itself as a private cord blood bank serving families who choose to store their newborn’s cord blood and cord tissue stem cells. In parallel, the company operates a public banking program in partnership with Duke University. According to multiple company news releases, Cryo-Cell’s public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the United States in prominent hospitals such as Cedars–Sinai Hospital in Los Angeles and Baptist Hospital in Miami. Earlier disclosures also reference more than 700 transplants and note that the public bank operates a cord blood donation site at Cedars–Sinai Hospital in Los Angeles.

Through this dual structure, Cryo-Cell participates in both family-directed storage and public donation models. The public program allows donated units to be used in transplant procedures, while private banking focuses on storage for potential family use.

Regulatory and quality framework

Cryo-Cell highlights a series of regulatory registrations and accreditations that frame its operations. The company reports that its facility is FDA registered, cGMP-/cGTP-compliant, and licensed in all U.S. states that require licensure for cord blood banking activities. In addition, Cryo-Cell is AABB accredited as a cord blood facility.

The company further notes that it was the first U.S. cord blood bank for private use only to receive FACT accreditation, which it describes as adherence to stringent cord blood quality standards set by an internationally recognized, independent accrediting organization. These registrations and accreditations are presented by the company as key elements of its quality and compliance framework.

PrepaCyte-CB and technology focus

Cryo-Cell states that it holds the exclusive rights to PrepaCyte-CB, which it describes as the cord blood banking industry’s most advanced cord blood processing technology. In its segment disclosures, the company identifies a manufacturing segment for PrepaCyte CB units, used to process umbilical cord blood stem cells. This technology focus aligns with the company’s broader role in cellular processing and cryogenic storage.

By combining proprietary processing technology with long-term storage services, Cryo-Cell integrates technology development with its core banking operations. The company’s SEC filings and news releases also reference research and development expenses related to agreements and clinical study support with Duke University.

Partnership with Duke University and cellular therapy strategy

In multiple public statements, Cryo-Cell describes a license agreement with Duke University entered into in February 2021. The company states that it believes this agreement has allowed Cryo-Cell to begin its transformation into an autonomous, vertically integrated cellular therapy company. The company also refers to a Clinical Study and Research Agreement with Duke to provide funding to complete the Duke IMPACT Study and to the development of a manufacturing laboratory related to the Duke License Agreement.

These disclosures indicate that, alongside its established cord blood banking operations, Cryo-Cell is investing in capabilities related to the development, manufacture, and administration of cellular therapies. The company’s stated mission includes the goal to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide.

ExtraVault and biostorage services

In March 2022, Cryo-Cell launched ExtraVault, which the company describes as a business that offers its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions. This initiative extends the company’s cryogenic storage and logistics capabilities beyond family and public cord blood banking into broader biostorage services.

The ExtraVault offering is presented as an application of Cryo-Cell’s experience in biostorage and distribution, providing services to organizations involved in biopharmaceutical development and healthcare delivery. This adds another dimension to the company’s operations alongside its core cord blood and tissue banking activities.

Mission and corporate purpose

Cryo-Cell articulates a mission to provide premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide, and to offer what it describes as the highest quality and most cost effective biostorage solutions available. This mission statement, repeated across several company news releases, connects its existing banking and storage operations with its cellular therapy ambitions and its ExtraVault biostorage services.

The company’s communications emphasize long-term storage of cord blood and cord tissue stem cells, public donation and transplantation support, technology development through PrepaCyte-CB, and expansion into cellular therapies and biostorage for institutional clients.

Capital structure, dividends, and credit facilities

Cryo-Cell’s SEC filings and news releases provide additional context on its capital allocation and financing. The company has announced regular quarterly cash dividends in the past and has also reported decisions not to declare dividends for certain quarters, citing factors such as profitability, economic conditions, financial performance, capital requirements, and strategic priorities. The company notes that future dividend decisions may change and that there is no assurance that future dividends will be paid.

In an 8-K filing, Cryo-Cell describes a Credit Agreement with Susser Bank that includes an unsecured revolving line of credit and a term loan facility. A Fifth Amendment to this Credit Agreement added the company’s wholly owned subsidiary, Celle Corp., as a guarantor, extended maturity dates for the revolving credit facility and term note, revised the revolving credit commitment, and adjusted applicable margins and commitment fees. These details illustrate how the company uses credit facilities as part of its financing strategy.

Corporate governance and stockholder matters

According to its definitive proxy statement, Cryo-Cell holds an annual meeting of stockholders to elect directors, ratify the appointment of independent registered public accountants, and conduct advisory votes on executive compensation. The proxy materials describe the company’s board structure, committees, and voting procedures, including the use of proxies, record dates, and quorum requirements.

The company’s 8-K filings also disclose the setting of the annual meeting date and record date and reference the company’s bylaws regarding the submission of business and director nominations by stockholders. These governance disclosures provide insight into how Cryo-Cell manages its stockholder relations and corporate decision-making processes.

Industry context based on company disclosures

While Cryo-Cell is classified under manufacturing and dental laboratories in some industry taxonomies, its own descriptions focus on cord blood banking, cord tissue cryopreservation, cellular processing, and cryogenic biostorage. Through its private and public cord blood banks, partnership with Duke University, proprietary PrepaCyte-CB technology, and ExtraVault biostorage services, the company positions itself within the broader fields of stem cell banking, cellular therapy development, and specialized biological storage.